HC Wainwright Reiterates “Buy” Rating for Replimune Group (NASDAQ:REPL)

HC Wainwright reaffirmed their buy rating on shares of Replimune Group (NASDAQ:REPL) in a report issued on Monday, Benzinga reports. The firm currently has a $17.00 price objective on the stock.

Several other research analysts have also recently weighed in on REPL. Wedbush reissued an outperform rating and issued a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. JPMorgan Chase & Co. cut their price objective on Replimune Group from $17.00 to $14.00 and set an overweight rating on the stock in a research report on Tuesday, August 13th. Barclays boosted their price objective on Replimune Group from $13.00 to $17.00 and gave the stock an overweight rating in a research report on Friday, June 7th. Roth Capital raised Replimune Group to a strong-buy rating in a research report on Tuesday, August 27th. Finally, Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They set a buy rating and a $17.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $16.20.

Replimune Group Trading Up 1.4 %

Shares of Replimune Group stock opened at $11.23 on Monday. The stock has a fifty day simple moving average of $10.27 and a 200 day simple moving average of $8.42. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.89. The company has a market capitalization of $689.69 million, a P/E ratio of -3.47 and a beta of 1.22. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. On average, sell-side analysts anticipate that Replimune Group will post -3.08 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.60% of the company’s stock.

Institutional Trading of Replimune Group

A number of institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its holdings in Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Millennium Management LLC increased its stake in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Vanguard Group Inc. increased its stake in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after acquiring an additional 32,555 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock worth $18,874,000 after acquiring an additional 1,679,553 shares during the last quarter. Finally, Rafferty Asset Management LLC increased its stake in Replimune Group by 148.1% in the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after acquiring an additional 276,596 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.